Clinical Trial Update: Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the safety and immunogenicity of SYS6017 in healthy participants aged 40 and older, targeting herpes zoster. The trial is currently no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• SYS6017

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Herpes Zoster | Phase 1 | Status: NOT_YET_RECRUITING